Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives

Clin Lung Cancer. 2019 Jan;20(1):1-6. doi: 10.1016/j.cllc.2018.09.016. Epub 2018 Sep 24.

Abstract

Patients with early-stage non-small-cell lung cancer undergo surgery with curative intent. Many of these patients relapse and, therefore, adjuvant therapies are important for improving survival of these patients. Adjuvant chemotherapy has been established and increases the 5-year survival rate. Here, we discuss systemic treatment strategies for further improving outcome of patients with completely resected non-small-cell lung cancer.

Keywords: Adjuvant chemotherapy; Immunotherapy; Prognosis; Surgery; Targeted therapy.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Chemotherapy, Adjuvant*
  • Cisplatin / therapeutic use*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Molecular Targeted Therapy
  • Pneumonectomy
  • Precision Medicine
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • pembrolizumab
  • Cisplatin